Ethyl 2-([5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate as a new potent oxyisobutyrate hypolipidaemic with unusual features.
Some compounds containing the N-imidazolyl and the ethyl oxy-isobutyrate groups linked to a naphthalene ring structure and some related analogues were synthesized and tested for hypolipidaemic activity. Ethyl 2-([5,6- dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate (V) proved to be a strong hypolipidaemic agent, several times more potent than clofibrate. Structural requirements for activity and differences from clofibrate analogues are discussed.
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology; D004032:Diet; D006937:Hypercholesterolemia / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D007093:Imidazoles / Q000138:chemical synthesis* / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D009281:Naphthalenes / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats
D000960:Hypolipidemic Agents; D007093:Imidazoles; D008077:Lipoproteins, LDL; D009281:Naphthalenes; C053573:ethyl 2-((5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl)oxy)-2-methylpropanoate; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate